Low Molecular Weight Complement Binder for Ocular Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for ocular fibrosis and wound healing are limited, with existing treatments like corticosteroids and ciclosporin A having non-specific efficacy and adverse effects, and conventional inhibitors such as monoclonal antibodies being unable to penetrate ocular tissues due to molecular weight restrictions and the blood-ocular barrier.
Innovation Solution
A binder, specifically a protein or protein fragment, is developed to bind to complement anaphylatoxins C5a, C3a, and C4a, inhibiting their activity and administered to promote wound healing, particularly in ocular tissues, with a molecular weight less than 90 kDa to ensure penetration through the cornea and other ocular structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to inhibit fibroblast activation, then therapeutic efficacy is improved, but molecular weight increases making penetration through the blood-ocular barrier impossible
Solution Approach 1:
The patent extracts only the essential antigen-binding portion of the monoclonal antibody (the Fab fragment or smaller binding domain), removing the heavy Fc portion that contributes to molecular weight but is not essential for the therapeutic mechanism of blocking fibroblast activation. This allows retention of therapeutic efficacy while achieving sufficient size reduction for ocular penetration.
Solution Approach 2:
The antibody molecule is segmented into functional domains, with only the antigen-binding variable regions being utilized for therapeutic effect. This segmentation allows the therapeutic action to be achieved with a fraction of the original molecular weight, enabling penetration through the blood-ocular barrier while maintaining the ability to bind and inhibit fibroblast activation.
2Object-affected harmful factors
If corticosteroids are used to treat ocular fibrosis, then anti-inflammatory effect is improved, but adverse effects such as cataract development and intraocular pressure elevation occur
Solution Approach 1:
The patent converts the harmful non-specific anti-inflammatory action of corticosteroids into a beneficial specific action by designing an inhibitor that selectively targets only the fibroblast activation pathway through specific antigen binding. This specificity eliminates the broad-spectrum side effects (cataract, intraocular pressure elevation) while preserving the desired anti-fibrotic effect.
Solution Approach 2:
The therapeutic agent is designed to act locally and specifically on fibroblast activation mechanisms rather than providing systemic anti-inflammatory coverage. This localized specific action at the molecular level (binding to specific antigens on fibroblasts) achieves anti-fibrotic effect without the broad hormonal effects of corticosteroids that cause adverse events.
3Reliability
If ciclosporin A is used to inhibit ocular fibrogenesis, then anti-fibrotic effect is improved, but onset of action is too slow for acute treatment
Solution Approach 1:
The patent replaces the slow immunomodulatory mechanism of ciclosporin A with a direct antigen-antibody binding mechanism. The inhibitor directly binds to fibroblast surface antigens and blocks activation signals immediately upon binding, eliminating the delayed onset associated with immunosuppressant metabolism and cellular uptake required by ciclosporin A.
Solution Approach 2:
The inhibitor is designed to bind directly to fibroblast activation antigens before significant fibrotic changes occur, preventing the activation process in its early stages. This preliminary blocking action at the antigen level provides rapid effect in acute settings, unlike ciclosporin A which requires time to modulate immune cell function and indirectly affect fibroblasts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binder effectively inhibits myofibroblast activation and transdifferentiation, reducing fibrosis and scarring by specifically targeting C5a and C3a, thereby promoting regular wound healing processes without the adverse effects of existing treatments and overcoming the molecular weight barrier.
Implementation Method 1
A binder, in particular a protein or protein fragment, binding to complement-anaphylatoxin C5a and/or C3a and/or C4a and thereby preferably thereby inhibiting the activity of C5a and/or C3a and/or C4a
Data Source
AI summary
Subject matter of the present invention is a binder, e.g. protein or protein fragment, binding to complement-anaphylatoxin C5a and/or C3a and/or C4a and thereby inhibiting the activity of C5a and/or C3a and/or C4a for use in the treatment of a subject having an ocular wound and/or fibrosis.